AzTrials
AzTrials

Cardiovascular DiseasesNCT00006514

Multivariate Risk of CVD in Diverse Populations

An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To statistically examine cardiovascular disease (CVD) risk in different populations based on data from studies representing national samples, cohort studies, and clinical trials. Read more about this study

Who is it for?
Ages Up to 100 years
Conditions the study is for
Cardiovascular Diseases, Heart Diseases
How many people
Not given
Where
No sites listed yet
Study dates
Sep 2000to Aug 2004
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 100 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

No eligibility criteria

About this study

To statistically examine cardiovascular disease (CVD) risk in different populations based on data from studies representing national samples, cohort studies, and clinical trials.

Read the detailed description

BACKGROUND:

Several algorithms have been developed to calculate multivariate risk of CVD based on characteristics associated with the disease. Framingham Heart Study data were used to develop the original algorithms, along with later models, using different mathematical forms, outcomes, and characteristics. Researchers then began to investigate the issue of generalizability, whether these risk estimates could be applied to new populations. For these algorithms to have general application, they must be able to rank risk correctly. And, when Framingham models were compared to new models developed for other studies, resulting orderings of risk were, in fact, similar.

The ability to order risk correctly, however, does not imply that estimated probabilities are right in terms of predicting disease for individuals. Methods are needed to assess individual risk to make treatment decisions, do cost-benefit analyses, and quantify benefits. These methods must be based on the patient's absolute risk, and existing equations may be incapable of establishing absolute risk across populations.

Earlier comparisons of multivariate risk among studies have made comparison populations as homogenous as possible before analysis. However, if multivariate risk estimates are to be truly useful, they must be applicable to the general population, and to be applicable, estimates must be based on comparisons of cohorts that include women and ethnic minorities. Also, in statistical terms, estimates must be robust enough to allow for minor shifts in methodologies for data collection and endpoint definition.

DESIGN NARRATIVE:

The heterogeneity of multivariate risk in different populations was examined based on data from studies representing national samples, cohort studies, and clinical trials. An analysis of these studies was conducted that included both sexes, various risk profiles, and representatives from several nationalities and ethnic groups. The pooled sample involved 20 studies, 233,833 participants, and over 47,000 deaths. Based on a common statistical approach, proportional hazards models were developed for each study to relate a set of essential characteristics to the prediction of CVD mortality. The characteristics included body mass index, age, blood pressure, serum cholesterol, smoking, and diabetes status. The models were then compared in terms of their ability to predict absolute risk of mortality across studies.

Secondary analyses were conducted to discover factors associated with inaccurate prediction and study characteristics associated with particular findings, such as interaction terms. An empirical examination was conducted of methods for adding newly discovered risk factors to existing prediction equations.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Medical subject headings
Cardiovascular Diseases, Heart Diseases

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2000 (estimated)
  2. Study startSep 2000
  3. Study completionAug 2004

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
IDs, dates and publications
ClinicalTrials.gov ID
NCT00006514
Sponsor's protocol ID
950
Other IDs
R01HL067460
Status last verified
Jul 2005
First submitted
20 Nov 2000
Last updated
18 Feb 2016
Results posted
No

Publications

  • Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med. 2003 Jul 28;163(14):1735-40. doi: 10.1001/archinte.163.14.1735.

    PubMed 12885690
  • Diverse Populations Collaboration. Smoking, body weight, and CHD mortality in diverse populations. Prev Med. 2004 Jun;38(6):834-40. doi: 10.1016/j.ypmed.2003.12.022.

    PubMed 15193906
  • Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med. 2005 Feb 28;165(4):430-5. doi: 10.1001/archinte.165.4.430.

    PubMed 15738373

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00006514, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in